PDF herunterladen
Thromb Haemost 1990; 64(03): 365-368
DOI: 10.1055/s-0038-1647320
Original Article
Schattauer GmbH

Increased Heparin Cofactor II Levels in Women Taking Oral Contraceptives

P Toulon
1   Laboratoire d’Hématologie, Hôpital Cochin, Paris, France
,
J M Bardin
2   Poste de Transfusion Sanguine, Hôpital Cochin, Paris, France
,
N M Blumenfeld
3   INSERM U 152, Hôpital Cochin, Paris, France
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 19. Januar 1990

Accepted after revision 18. Juni 1990

Publikationsdatum:
04. September 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

Heparin cofactor II (HCII) is a thrombin inhibitor present in human plasma whose activity is enhanced by heparin. HCII exhibits important homologies with antithrombin III, the main heparin-enhanced thrombin inhibitor. Cases of recurrent thromboembolism have been recently reported in patients with HCII deficiency. Since the use of oral contraceptives (OC) is associated with an increased risk of thrombosis, the study of the plasma levels of HCII was undertaken in women taking contraceptive pills. Plasma HCII levels were found significantly higher in 62 women taking low-estrogen content OC (1.20 ± 0.28 U/ml) than in 62 age matched women not taking OC (0.94 ± 0.16 U/ml) or in 62 men (0.96 ± 0.19 U/ml). Significant correlations between HCII and fibrinogen levels were reported in the three groups. From the pooled data of the two control groups (men and women not taking OC), the normal range for plasma HCII levels was defined to be between 0.60 and 1.30 U/ml (mean ± 2 SD). Two cases of low HCII levels (<0.60 U/ml) were found in the control groups, but none in the group of women taking OC. It is concluded that the use of oral contraceptives is associated with a rise in HCII levels and that the screening for HCII deficiency has to be performed at distance of any OC therapy.

 

  • References

  • 1 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
    CrossrefPubMedGoogle Scholar
  • 2 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-2225
    PubMedGoogle Scholar
  • 3 Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM. cDNA sequence, chromosome localization, restriction fragment length polymorphism and expression of heparin cofactor II in Escherichia coli. Biochemistry 1988; 27: 752-759
    CrossrefPubMedGoogle Scholar
  • 4 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
    PubMedGoogle Scholar
  • 5 Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J Biol Chem 1985; 260: 3501-3505
    PubMedGoogle Scholar
  • 6 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
    PubMedGoogle Scholar
  • 7 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diathes Haemorrh 1965; 13: 516-530
    PubMedGoogle Scholar
  • 8 Tian TH, Marbet GA, Duckert E. Association of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985; ll: 413-414
    PubMedGoogle Scholar
  • 9 Sié P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; II 414-416
    PubMedGoogle Scholar
  • 10 Bertina RM, van der Linden IK, Engeser L, Muller HP, Brommer EJ P. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemostas 1987; 57: 196-200
    PubMedGoogle Scholar
  • 11 Toulon PA, Vitoux JR, Fiessinger JN, Sultan Y, Aiach M. Heparin cofactor II deficiency: a risk factor for thrombosis. Circulation 1988; 78 suppl. II 326
    PubMedGoogle Scholar
  • 12 Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-pg oestrogen preparations. Br Med J 1980; 280: 1157-1161
    CrossrefPubMedGoogle Scholar
  • 13 Bottinger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; l: 1097-1101
    PubMedGoogle Scholar
  • 14 Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305: 612-618
    CrossrefPubMedGoogle Scholar
  • 15 Hedlin AM. The effect of oral contraceptive estrogen on blood coagulation and fibrinolysis. Thromb Diathes Haemorrh 1975; 33: 370-378
    PubMedGoogle Scholar
  • 16 Meade TW, Brozovic M, Chakrabarti R, Howarth DJ, North WR S, Stirling Y. An epidemiological study of the haemostatic and other effects of oral contraceptives. Br J Haematol 1976; 34: 353-364
    CrossrefPubMedGoogle Scholar
  • 17 Poller L. Oral contraceptives, blood clotting and thrombosis. Br Med Bull 1978; 34: 151-156
    CrossrefPubMedGoogle Scholar
  • 18 Carvalho AC A, Vaillancourt RA, Cabral RB, Lees RS, Colman RW. Coagulation abnormalities in women taking oral contraceptives. JAMA 1977; 237: 875-878
    CrossrefPubMedGoogle Scholar
  • 19 Mannucci PM, Tlipodi A. Laboratory screening of inherited thrombotic syndromes. Thromb Haemostas 1987; 57: 247-251
    PubMedGoogle Scholar
  • 20 Sagar S, Stamatakis JD, Thomas DR, Kakkar VV. Oral contraceptives, antithrombin-Ill activity, and postoperative deep-vein thrombosis. Lancet 1976; 1: 509-511
    PubMedGoogle Scholar
  • 21 Gilabert J, Fernandez JA, Espana F, Aznar J, Estelles A. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988; 49: 319-329
    CrossrefPubMedGoogle Scholar
  • 22 Gonzales R, Alberca I, Vicente V. Protein C levels in late pregnancy, postpartum and in women on oral contraceptives. Thromb Res 1985; 39: 637-640
    CrossrefPubMedGoogle Scholar
  • 23 Cohen H, Mackie IJ, Walshe K, Gillmer MD G, Machin SJ. A comparison of the effects of two triphasic oral contraceptives on haemostasis. Br J Haematol 1988; 69: 259-263
    CrossrefPubMedGoogle Scholar
  • 24 Meade TW, Stirling I, Wilkes H, Mannucci PM. Effects of oral contraceptives and obesity on protein C antigen. Thromb Haemostas 1985; 53: 198-199
    PubMedGoogle Scholar
  • 25 Huisweld IA, Hospers JE H, Meijers JC M, Starkenburg AE, Erich WB M, Bouma BN. Oral contraceptives reduce total protein S, but not free protein S. Thromb Res 1987; 45: 109-14
    CrossrefPubMedGoogle Scholar
  • 26 Teien AN, Abildgaard U, Höök M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8: 859-867
    CrossrefPubMedGoogle Scholar
  • 27 Toulon P, Jacquot C, Capron L, Frydman MO, Vignon D, Aiach M. Antithrombin III and heparin cofactor II in patients with chronicrenal failure undergoing regular hemodialysis. Thromb Haemostas 1987; 57: 263-268
    PubMedGoogle Scholar
  • 28 Leipnitz G, Miyashita C, Heiden M, von Blohn G, Kcihler M, Wenzel E. Reference values and variability of plasminogen in healthy blood donors and its relation to parameters of the fibrinolytic system. Haemostasis 1988; 18 (Suppl. 01) suppl 61-68
    PubMedGoogle Scholar
  • 29 Franchi F, Tripodi A, Valsecchi C, Mannucci PM. Functional assay of protein C: comparison of two snake-venom assays with two thrombin assays. Thromb Haemostas 1988; 60: 145-147
    PubMedGoogle Scholar
  • 30 von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 31 Ezenagu LC, Brandt JT. Laboratory determination of heparin cofactor II. Arch Pathol Lab Med 1986; 110: 1149-1151
    PubMedGoogle Scholar
  • 32 Sandset PM, Hellgren M, Uvebrandt M, Bergstrcim H. Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy. Thromb Res 1989; 55: 665-670
    CrossrefPubMedGoogle Scholar
  • 33 Andersson TR, Larsen ML, Handeland GE, Abildgaard U. Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population. Scand J Haematol 1986; 36: 96-102
    PubMedGoogle Scholar
  • 34 Sié P, Dupouy D, Pichon J, Boneu B. Turn over study of heparin cofactor II in healthy man. Thromb Haemostas 1985; 54: 635-638
    PubMedGoogle Scholar
  • 35 Sié P, Lansen J, Lacheretz F, Vershuere B, Boneu B. Comparative turn over of heparin cofactor II and antithrombin III in baboons. Influence of heparin and pentosan polysulfate administration. Thromb Haemostas 1986 56. 302-307
    PubMedGoogle Scholar
  • 36 Meade TW, North WR S, Chakrabarti R, Stirlirg X, Haines AR, Thompson SG, Brozovic M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050-1054
    PubMedGoogle Scholar
  • 37 Massouh M, Jatoi A, Gordon EM, Ratnoff OD. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. J Lab Clin Med 1989; 114: 697-699
    PubMedGoogle Scholar